uz
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Kanalga Telegramโ€™da oโ€˜tish

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Ko'proq ko'rsatish

๐Ÿ“ˆ Telegram kanali ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ analitikasi

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) Arab til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 13 326 obunachidan iborat bo'lib, Tibbiyot toifasida 1 931-o'rinni va Saudiya Arabistoni mintaqasida 5 703-o'rinni egallagan.

๐Ÿ“Š Auditoriya koโ€˜rsatkichlari va dinamika

ะฝะตะฒั–ะดะพะผะพ sanasidan buyon loyiha tez oโ€˜sib, 13 326 obunachiga ega boโ€˜ldi.

29 Iyun, 2026 dagi oxirgi maโ€™lumotlarga koโ€˜ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 168 ga, soโ€˜nggi 24 soatda esa -26 ga oโ€˜zgardi va umumiy qamrov yuqori darajada qolmoqda.

  • Tasdiqlash holati: Tasdiqlanmagan
  • Jalb etish (ER): Auditoriya oโ€˜rtacha 28.47% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining 9.84% ini tashkil etuvchi reaksiyalarni toโ€˜playdi.
  • Post qamrovi: Har bir post oโ€˜rtacha 3 795 marta koโ€˜riladi; birinchi sutkada odatda 1 312 ta koโ€˜rish yigโ€˜iladi.
  • Reaksiyalar va oโ€˜zaro taโ€™sir: Auditoriya faol: har bir postga oโ€˜rtacha 37 ta reaksiya keladi.
  • Tematik yoโ€˜nalishlar: Kontent ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ kabi asosiy mavzularga jamlangan.

๐Ÿ“ Tavsif va kontent siyosati

Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida taโ€™riflaydi:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Yuqori yangilanish chastotasi (oxirgi maโ€™lumot 30 Iyun, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli boโ€˜lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim taโ€™sir nuqtasiga aylantirishini koโ€˜rsatadi.

13 326
Obunachilar
-2624 soatlar
+2647 kunlar
+16830 kunlar
Postlar arxiv
https://docs.google.com/forms/u/2/d/1PTJUufYQCbUXZQ-WJC67gppzc9ruFjQXzH9oHz9jWAg/edit?usp=sharing_eil_se_dm&ts=6908537c ุงุฐุง ุงู…ูƒู† ู…ุณุงุนุฏุฉ ุฒู…ู„ุงุฆูƒู… ุจู…ู„ุฆ ู‡ุฐุง ุงู„ุงุณุชุจูŠุงู†

Multidrug-Resistant ุญุฌูŠ ูƒุจูŠุฑ ุจุงู„ุนู…ุฑ ูŠุนุงู†ูŠ ู…ู† ุงู„ุชู‡ุงุจุงุช ููŠ ุงู„ู…ุณุงู„ูƒ ุงู„ุจูˆู„ูŠุฉ ู†ุชูŠุฌุฉ ุงู„ุตุฑู ุบูŠุฑ ุงู„ู…ุจุฑุฑ ูˆ ุงู„ุงุณุชุฎุฏุงู… ุงู„ุฎุงุทุฆ ู„ู„ู…ุถุงุฏุงุช ุง
Multidrug-Resistant ุญุฌูŠ ูƒุจูŠุฑ ุจุงู„ุนู…ุฑ ูŠุนุงู†ูŠ ู…ู† ุงู„ุชู‡ุงุจุงุช ููŠ ุงู„ู…ุณุงู„ูƒ ุงู„ุจูˆู„ูŠุฉ ู†ุชูŠุฌุฉ ุงู„ุตุฑู ุบูŠุฑ ุงู„ู…ุจุฑุฑ ูˆ ุงู„ุงุณุชุฎุฏุงู… ุงู„ุฎุงุทุฆ ู„ู„ู…ุถุงุฏุงุช ุงู„ุญูŠูˆูŠุฉ ู…ู† ู‚ุจู„ ู„ู„ู…ุฑูŠุถ ูƒุงุฑุซุฉ ูˆุงู„ู„ู‡ ุงู„ูˆุญูŠุฏ ุงู„ูŠ ู…ู…ูƒู† ูŠุณุชุฌูŠุจ ุงู„ู‡ ู‡ูˆ Tigecycline

ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุงุญู†ู‡ ุทู„ุงุจ ูƒู„ูŠุฉ ุงู„ุตูŠุฏู„ุฉ _ ุงู„ู…ุฑุญู„ู‡ ุงู„ุฎุงู…ุณู‡ ุนุฏู†ุง ุจุญุซ ุชุฎุฑุฌ ูˆู‡ุฐุง ุงุณุชุจูŠุงู† ูŠุฎุต ุงู„ุจุญุซ ุจู„ุง ุฒุญู…ู‡ ุนู„ูŠูƒู… ุชูƒุฏุฑูˆู† ุชุณุงุนุฏูˆู†ู‡ ุจุฏู‚ูŠู‚ู‡ ู…ู† ูˆู‚ุชูƒู… ูˆุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ู‡ุฐุง ูˆุดูƒุฑุงู‹ ู…ู‚ุฏู…ุงู‹ https://docs.google.com/forms/d/e/1FAIpQLScGe57JSan3P32y8GNr4iTXPoVm19cMV6_nE6f33APGEGxTvA/viewform?usp=header ุงู„ุตูุฑ ู„ุง ุชู†ุทุจู‚ ูค- ุชู†ุทุจู‚ ุฌุฏุงู‹ ุงู„ ูกุŒูข- ุชู†ุทุจู‚ ู…ุนุธู… ุงู„ูˆู‚ุช

ุงุฎูˆุงู† ุณุงุนุฏูˆุง ุฒู…ู„ุงุฆูƒู… ุจู…ู„ุฆ ุงู„ุงุณุชุจูŠุงู†ุงุชโ™ฅ๏ธ

- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุงุญู†ุง ุทู„ุงุจ ุตูŠุฏู„ุฉ ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ุนุฏู†ุง ุจุญุซ ูŠู‡ุฏู ุฅู„ู‰ ู…ู‚ุงุฑู†ุฉ ุงู„ุงุซุงุฑ ุงู„ุฌุงู†ุจูŠุฉ ูˆุชุญู…ู„ ุงู„ู…ุฑูŠุถ ู„ู„ู…ูŠุชููˆุฑู…ูŠู† ู…ู‚ุงุจู„ ู…ุซุจุทุงุช DPP4 inhibitors ูŠุง ุฑูŠุช ุชุดุงุฑูƒูˆู†ู‡ ุฑุฆูŠูƒู… ูˆุชู†ุทูˆู†ู‡ ุฌุฒุก ุจุณูŠุท ู…ู† ูˆู‚ุชูƒู… ุชู…ู„ูˆู† ู‡ุฐุง ุงู„ุงุณุชุจูŠุงู† ๐ŸŒธ https://docs.google.com/forms/d/1EdInAEsPRrpWhN590WCoHnS5CqnFaF0mHuUrsxGOoiA/viewform

Dyslipidemia Arrhythmia Thrombosis ุงู„ู…ูˆุงุถูŠุน ุงู„ู‚ุงุฏู…ุฉ ุฅู† ุดุงุก ุงู„ู„ู‡ ูˆุจุนุฏู‡ุง ุงุฐุง ุงูƒูˆ ูˆู‚ุช ุงุดุฑุญ ูƒู… ู…ูˆุถูˆุน ูˆุงุฐุง ู…ุงูƒูˆ ู ุงุนุชุฐุฑ ุนู† ุงูƒู…ุงู„ ุงู„ุฌุฒุก ุงู„ุจุงู‚ูŠ ู„ุงู† ู„ุงุฒู… ุงุจุฏูŠ ุงุดุฑุญ ุงู„ู…ุงุฏุฉ ุงู„ูˆุฒุงุฑูŠุฉ

ุทู„ุงุจ ุงู„ูŠ ุนู†ุฏู‡ ุดุฑุญ ุฒูŠู† ู„ู„ูƒูŠู…ูŠุงุก ุณุฑูŠุฑูŠุฉ ุฏุฒูˆู‡ู† ุจุงู„ุชุนู„ูŠู‚ุงุช

The first-choice vasopressor in septic shock in patient suffer from tachydysarrhmia is: A. Norepinephrine B. Dobutamine C. Epinephrine D. Phenylephrin

From the previous case. What is the MAP: A) 30 B) 40 C) 50 D) 60 E) None of the above

A previously fit 35-year-old man presents to emergency department with septic shock secondary to arm cellulitis. He is cold peripherally and slightly confused. His HR is 125/min NSR, BP 60/30 mmHg, Respiratory rate 25/min. if his weight is 60 kg, his initial management should be:
A)Start IV fluid 1000 mL in 1 hour B)Start IV fluid 2000 mL in 1 hour C)Start Noradrenaline D)Start Dobutamine E)Start Dopamine

ุงุฎูŠุฑุง๐Ÿ™‚โ€โ†•๏ธ

- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ู†ุดุชุบู„ ุนู„ู‰ ุจุญุซ ุงู„ุชุฎุฑุฌ ุงู„ุนู†ูˆุงู† ุนู† ุงู†ุชุดุงุฑ ูู‚ุฑ ุงู„ุฏู… ุจูŠู† ุทู„ุงุจ ุงู„ุฌุงู…ุนุงุช ู†ุฑุฌูˆ ู…ู†ูƒู… ุงู„ุชูุถู„ ุจุงู„ู…ุดุงุฑูƒุฉ ููŠ ู‡ุฐุง ุงู„ุงุณุชุจูŠุงู† ูˆุดูƒุฑุง https://docs.google.com/forms/d/e/1FAIpQLSdSudGo_7m3_V1oPehUFuDtkXSDAi4RCXviFm_GlclY4GpNkA/viewform?usp=dialog

- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ู„ุทูุงู‹ ู…ู…ูƒู† ู…ู„ุฆ ุงู„ุงุณุชุจูŠุงู† ุŒ ุฑุงุฆูŠูƒู… ูŠู‡ู…ู†ุง https://docs.google.com/forms/d/e/1FAIpQLSd2Avx91uJHMJpKelXQDLj4j91SyvK1bIBMdfmC30opZAip6w/viewform?usp=header